LPCN Lipocine Inc.
1.930USD-12.27%Mkt Cap: 15.91M $P/E: —1d ago
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone repl…
Industry Peers
Biotechnology$127.47BUSDP/E 29.3
$78.65BUSD
$76.14BUSDP/E 18.3
$51.48BUSDP/E 31.2
$48.23BUSDP/E 31.4
$41.82BUSDP/E 17.8
$40.32BUSD
$39.83BUSDP/E 62.6
$32.48BUSDP/E 29.9
$30.04BUSDP/E 37.9
$24.71BUSD
$23.13BUSD
$22.85BUSDP/E 14.4
$22.17BUSDP/E 28.4
$21.94BUSD
$21.10BUSDP/E 29.1
$14.65BUSDP/E 17.1
$14.62BUSDP/E 18.6
$14.44BUSDP/E 15.2
$13.70BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
 Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock? Lipocine (LPCN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. | ||